{"source": ["Bleeding time was long considered to be the appropriate test for evaluating primary hemostasis, and it was performed on up to 40% of patients with cirrhosis. Nevertheless, the clinical relevance of its findings has not been established.", "Bleeding does not hurt, they say.", "Patients with PE received initial anticoagulant therapy with low molecular weight heparins LMWH initially and later warfarin was maintained for minimum 6 months.", "The therapy used will depend on the type of coronary artery disease.", "controlling the bleeding.", "When severe dehydration occurs it causes acute stroke, clot formation, aggravation of chronic lung conditions, cardiac complications, renal dysfunction, and psychiatric disorders.", "Among patients with advanced cirrhosis almost 90% of the platelets can be stored in the spleen. These patients usually have a moderately low count of peripheral platelets 19.", "Since this complex is the most important receptor for fibrinogen, its inactivation prevents fibrinogen bonding to platelets, and this finally inhibits platelet aggregation, and platelets remain altered for the rest of their lives.", "Bleeding in the area cannot be controlled.", "Sterile tubes with 3.8% sodium citrate were used as anticoagulant.", "43 Moreover, there are no management guidelines to help define the precise indications and contraindications in these types of patients, and the use of thromboelastrography may be of help 44.", "The intra-operative transfused volume in this study was 27.9cc/kg SD=15.7, which correlates with transfusion requirements published in the world literature. For Goobie et al. the mean transfusion value during surgery was 33 cc/kg SD = 13, and the PRBCs used postoperatively were 3 cc/kg 95% CI between 0 and 25, whereas Dadure et al. report an intra-operative transfused volume of 1.6 cc/kg in the tranexamic acid group vs. 11 cc/kg in the placebo group p = 0.01.", "Thromboelastography is emerging as a diagnostic tool and as a guide for therapy, but additional randomized clinical trials are required to assess its use.", "7. Monitor coagulation at admission thromboelastography or coagulation tests until the coagulopathy has been corrected and the bleeding stopped.", "In this regard, Bof-fard's study is striking, because while transfusion is the gold standard, it lacks effectiveness due to the absence of an environment conducive to coagulation and cell perfusion; it is interesting that the adequate control of systolic blood pressure SPB TAS >90, platelets >100,000 and arterial pH > 7.2 resulted in improved overall survival, as referenced by Jim\u00e9nez et al. in 2010, with a much more specific analysis for each entity.", "While the decision to transfuse is obvious in some cases, in most scenarios it requires clinical measurement of relevant variables.", "Thrombin is a very active platelet recruiting agent and gives positive feedback because it can also activate factors V, VIII and XI.", "HTS comes in different concentrations - 2%, 3%, 7.5%, and 23.4% - and the recommendation is that if it needs to be used at a >2% it must be delivered through a central line, thus avoiding the risk of thrombophlebitis and peripheral vein thrombosis; bolus doses result in a lower rate of phlebitis.", "It is usual to have in the OR patients receiving prophylactic or therapeutic anticoagulation with low molecular weight heparins LMWH, even a few hours prior to surgery. This generates concern about the right timing between the last dose of LMWH and the surgical procedure or the induction of regional anesthesia.", "Intra-operative bleeding rates were consistent with the reports from other authors, but analysis of bleeding associated with different pro-coagulation strategies revealed some differences. For Goobie et al. in an experiment using tranexamic acid in patients undergoing craniosynostosis correction, there was less haemorrhage in the tranexamic acid group 62 cc/kg, DE = 22 compared to placebo 101 cc/kg, SD = 63.", "Even though hypothermia, acidosis and coagulation factor dilution secondary to crystaloid reanimation have an important role; current evidence suggests tissue damage, hypoperfusion, accelerated fibrinolysis and inflammatory are also crucial for the development of coagulopathy. 1. Dilutional coagulopathy: Dilution of coagulation factors and platelets after large volume infusion coloids, crystaloids in initial reanimation for preserving circulation volume.", "Although temporary controlled hypotension may allow surgical control of the bleeding, it may result in worse outcomes.", "Be very careful with the metabolic requirements of the patient since these are reduced in up to 50% and monitor coagulation, although different trials do not show a significant risk of bleeding. Hypothermia extends the half-life of all drugs.", "Antegrade cardioplegia was used with an infusion of 1000 cc of custodiol, the bleeding calculated was 500 cc, 2 units of packed red blood cells PRBC and 2 units of fresh frozen plasma FFP are transfused during surgery.", "As concerns the Reflection Article \u201cBlood Storage and Transfusion Injury\u201d written in relation with the article entitled \u201cBlood Sparing Techniques in Surgery\u201dthat proposes that a bank blood undergoes \u201cstorage\u201d alterations leading to worse outcomes when \u201cold\u201d units are transfused, it is worth highlighting that studies with intermediate outcomes such as lung dysfunction, have not found statistical differences between transfusions using blood with different storage times, in particular in the ICU; while other studies report alterations, particularly in mass transfusions and trauma cases.", "Anti-platelet therapy is nowadays considered essential for those patients who are at risk to sustain strokes cerebro-vascular events, thrombus formation, as well as in cases of coronary valvular prostheses stents.", "\u2022 Identifies hypercoagulability, particularly in trauma and surgery and helps to predict postoperative thrombotic events 7,8.", "There is little research about the use of hyperosmolar therapies in patients with ischaemic stroke, and there is no uniform approach to its use.", "The continuous release of FXa, fibrin and thrombin leads to the activation of the fibrinolytic system Figure 2.", "Moreover, they suggest the use of TEG for heparin reversal, given that results are available within a short period of time to help guide the definitive therapy and reduce the number of unnecessary transfusions.", "If the pre-anesthesia evaluation suggest a history of bleeding, the patient shall be referred to the hematologist for analysis before surgery and be prepared during the procedure according to the coagulation disorder diagnosed.", "In addition, red blood cell transfusions may be needed to restore the oxygen transportation capacity of the blood 7 mg/dL of hemoglobin or less 34.", "Any condition that affects liver functioning has potential repercussions for coagulation. In advanced chronic liver disease alterations in hemostasis are even more evident in both procoagulant and anticoagulant substances.", "Normal volume hemodilution is accepted if blood extracted via phlebotomy does not lose contact with the patient's circulation. Erythropoietin and desmopressin are also accepted treatment options.", "The extent and severity of the coagulopathy in these patients had been predicted, but was not clearly understood, the mechanisms by which sudden changes of plasma electrolytes and causes of the metabolic acidosis were not fully appreciated.", "If Factor VIII is not available then Cryoprecipitate is next choice of blood product in the management of haemophilia A, which provides 80 units of factor VIII per bag.", "Threshold Hematocrit: Minimum allowable hematocrit before making the decision to transfuse; this is a theoretical concept derived from reducing the actual hematocrit of the patient by 30 %, or by 20 % in stable cardiopulmonary pathology and even by 10 % in the critical patient; the end value should be less than 25 %.", "Blood collected in anticoagulant bags citrate phosphate dextrose adenine: CPDA is weighed, labeled and stored in the fridge in the operating room. The blood is infused into the patient once the procedure is finished. It can be used up to 24 h later, but it is best to do so within the first 6h because platelet function is preserved.", "Treatment: Treatment must be undertaken when platelet count is below 20,000/mm, or when there are data of diffuse haemorrhage. All other cases must be individually assessed:"], "hyp": ["\u957f\u671f\u4ee5\u6765,\u4eba\u4eec\u4e00\u76f4\u8ba4\u4e3a\u51fa\u8840\u65f6\u95f4\u662f\u8bc4\u4f30\u521d\u7ea7\u809d\u9ebb\u75f9\u7684\u9002\u5f53\u68c0\u9a8c\u6807\u51c6,\u5bf9\u591a\u8fbe40%\u7684\u809d\u786c\u5316\u75c5\u4eba\u8fdb\u884c\u4e86\u68c0\u67e5,\u4f46\u7ed3\u679c\u7684\u4e34\u5e8a\u76f8\u5173\u6027\u5c1a\u672a\u786e\u5b9a\u3002", "\u4ed6\u4eec\u8bf4,\u6d41\u8840\u5e76\u4e0d\u75db\u3002", "\u60a3\u6709\u767d\u5589\u3001\u7834\u4f24\u98ce\u548c\u767e\u65e5\u54b3\u7684\u75c5\u4eba\u521d\u6b65\u63a5\u53d7\u4e86\u4f4e\u5206\u5b50\u91cd\u91cf\u809d\u708e\u7684\u6297coagulant\u7597\u6cd5,\u6700\u521d\u548c\u540e\u6765\u7684Warfarin\u81f3\u5c11\u4fdd\u6301\u4e866\u4e2a\u6708\u3002", "\u4f7f\u7528\u7684\u7597\u6cd5\u5c06\u53d6\u51b3\u4e8e\u51a0\u72b6\u52a8\u8109\u75be\u75c5\u7684\u7c7b\u578b\u3002", "\u63a7\u5236\u51fa\u8840", "\u5f53\u53d1\u751f\u4e25\u91cd\u8131\u6c34\u65f6,\u4f1a\u5bfc\u81f4\u6025\u6027\u4e2d\u98ce\u3001\u51dd\u5757\u5f62\u6210\u3001\u6162\u6027\u80ba\u75c5\u6076\u5316\u3001\u5fc3\u810f\u75c5\u5e76\u53d1\u75c7\u3001\u80be\u529f\u80fd\u969c\u788d\u548c\u7cbe\u795e\u7d0a\u4e71\u3002", "\u5728\u809d\u786c\u5316\u7a0b\u5ea6\u8f83\u9ad8\u7684\u60a3\u8005\u4e2d,\u8fd190%\u7684\u8840\u5c0f\u677f\u53ef\u4ee5\u50a8\u5b58\u5728\u813e\u810f\u4e2d,\u8fd9\u4e9b\u75c5\u4eba\u7684\u8fb9\u7f18\u5c0f\u677f\u901a\u5e38\u6570\u91cf\u8f83\u4f4e,\u53ea\u670919\u4e2a\u3002", "\u7531\u4e8e\u8fd9\u4e2a\u7efc\u5408\u4f53\u662f\u7ea4\u7ef4\u7d20\u6700\u91cd\u8981\u7684\u53d7\u4f53,\u56e0\u6b64\u5b83\u7684\u4e0d\u6d3b\u5316\u9632\u6b62\u4e86\u7ea4\u7ef4\u7d20\u4e0e\u5c0f\u677f\u5757\u7684\u7ed3\u5408,\u8fd9\u6700\u7ec8\u6291\u5236\u4e86\u5c0f\u677f\u5757\u7684\u805a\u96c6,\u5c0f\u677f\u5757\u5728\u5176\u4f59\u751f\u4e2d\u4ecd\u7136\u88ab\u6539\u53d8\u3002", "\u4e0d\u80fd\u63a7\u5236\u8be5\u5730\u533a\u7684\u51fa\u8840\u3002", "\u542b\u67093.8%\u94a0\u67e0\u6aac\u9178\u94a0\u7684\u6d88\u6bd2\u7ba1\u88ab\u7528\u4f5c\u6297\u51dd\u80f6\u5242\u3002", "43 \u6b64\u5916,\u6ca1\u6709\u5236\u5b9a\u7ba1\u7406\u51c6\u5219,\u5e2e\u52a9\u786e\u5b9a\u8fd9\u7c7b\u75c5\u4eba\u7684\u51c6\u786e\u8ff9\u8c61\u548c\u8fdd\u89c4\u73b0\u8c61,\u4f7f\u7528\u8840\u6e05\u8868\u8c31\u672f\u4e5f\u8bb8\u6709\u5e2e\u52a944\u3002", "\u8fd9\u9879\u7814\u7a76\u4e2d\u624b\u672f\u671f\u95f4\u7684\u8f93\u8840\u91cf\u4e3a33cc/kg SD=13,\u624b\u672f\u671f\u95f4\u7684\u5e73\u5747\u8f93\u8840\u4ef7\u503c\u4e3a33cc/kg SD=13,\u624b\u672f\u540e\u4f7f\u7528\u7684PRBC\u4e3a3cc/kg 95% CI\u57280\u81f325\u4e4b\u95f4,\u800cDadure\u7b49\u4eba\u62a5\u544a\u8bf4,\u5728Tranexamic\u9178\u7c7b\u4e2d,\u624b\u672f\u671f\u95f4\u7684\u8f93\u8840\u91cf\u4e3a1.6 cc/kg,\u800c\u5728Probo\u7ec4\u4e2d,\u4e3a11cc/kg,p=0.01\u3002", "\u8840\u6d46\u6210\u50cf\u6cd5\u6b63\u5728\u6210\u4e3a\u4e00\u79cd\u8bca\u65ad\u5de5\u5177\u548c\u6cbb\u7597\u6307\u5357,\u4f46\u8fd8\u9700\u8981\u989d\u5916\u7684\u968f\u673a\u4e34\u5e8a\u8bd5\u9a8c\u6765\u8bc4\u4f30\u5176\u4f7f\u7528\u60c5\u51b5\u3002", "7. \u76d1\u6d4b\u5f55\u7528\u8840\u538b\u6210\u50cf\u6216\u51dd\u56fa\u8bd5\u9a8c\u7684\u51dd\u56fa\u60c5\u51b5,\u76f4\u81f3\u51dd\u56fa\u75c5\u75c7\u5f97\u5230\u7ea0\u6b63\u5e76\u6b62\u8840\u3002", "\u5728\u8fd9\u65b9\u9762,Bof-fard\u7684\u7814\u7a76\u662f\u60ca\u4eba\u7684,\u56e0\u4e3a\u8f93\u8840\u662f\u91d1\u672c\u4f4d,\u4f46\u7531\u4e8e\u7f3a\u4e4f\u6709\u5229\u4e8e\u51dd\u805a\u548c\u7ec6\u80de\u6e17\u5165\u7684\u73af\u5883,\u56e0\u6b64\u7f3a\u4e4f\u6548\u529b;\u6709\u8da3\u7684\u662f,\u5145\u5206\u63a7\u5236\u9759\u8109\u8840\u538bSPB TAS>90\u3001\u5c0f\u677f>100 000\u548c\u52a8\u8109pH > 7.2,\u4f7f\u603b\u4f53\u751f\u5b58\u5f97\u5230\u6539\u5584,\u5982Jim\u00e9nez\u7b49\u4eba2010\u5e74\u63d0\u5230\u7684\u90a3\u6837,\u6bcf\u4e2a\u5b9e\u4f53\u90fd\u8fdb\u884c\u4e86\u66f4\u4e3a\u5177\u4f53\u7684\u5206\u6790\u3002", "\u867d\u7136\u5728\u67d0\u4e9b\u60c5\u51b5\u4e0b\u8f6c\u53e3\u51b3\u5b9a\u662f\u663e\u800c\u6613\u89c1\u7684,\u4f46\u5728\u5927\u591a\u6570\u60c5\u51b5\u4e0b,\u8f6c\u53e3\u51b3\u5b9a\u8981\u6c42\u5bf9\u76f8\u5173\u53d8\u6570\u8fdb\u884c\u4e34\u5e8a\u6d4b\u91cf\u3002", "Throwombin\u662f\u4e00\u4e2a\u975e\u5e38\u6d3b\u8dc3\u7684\u62db\u751f\u5c0f\u677f\u677f\u7684\u4ee3\u7406\u5546,\u63d0\u4f9b\u79ef\u6781\u7684\u53cd\u9988,\u56e0\u4e3a\u5b83\u4e5f\u80fd\u6fc0\u6d3b\u56e0\u7d20\u4e94\u3001\u516b\u548c\u5341\u4e00\u3002", "HTS\u7684\u6d53\u5ea6\u4e0d\u540c -- -- 2%\u30013%\u30017.5%\u548c23.4% -- -- \u5efa\u8bae\u662f,\u5982\u679c\u9700\u8981\u4f7f\u7528\u5927\u4e8e2%\u7684HTS,\u5219\u5fc5\u987b\u901a\u8fc7\u4e2d\u5fc3\u7ebf\u63d0\u4f9b,\u4ece\u800c\u907f\u514d\u8840\u6813\u8840\u6813\u548c\u5468\u8fb9\u9759\u8109\u8840\u6813\u7684\u5371\u9669;bolus\u5242\u91cf\u5bfc\u81f4\u8840\u6e05\u708e\u53d1\u75c5\u7387\u8f83\u4f4e\u3002", "\u901a\u5e38\u60c5\u51b5\u4e0b,\u5728\u624b\u672f\u524d\u51e0\u5c0f\u65f6,\u5728\u624b\u672f\u5ba4\u63a5\u53d7\u4f4e\u5206\u5b50\u91cd\u91cf\u809d\u810f\u809d\u810f\u809d\u810f\u7684\u9884\u9632\u6027\u6216\u6cbb\u7597\u6027\u6297\u51dd\u7ed3\u7684\u75c5\u4eba,\u751a\u81f3\u5728\u624b\u672f\u524d\u51e0\u5c0f\u65f6,\u90fd\u4f1a\u53d7\u5230\u9884\u9632\u6216\u6cbb\u7597\u6027\u6297\u51dd\u7ed3\u4f5c\u7528\u7684\u75c5\u4eba\u7684\u5f71\u54cd,\u8fd9\u5c31\u5f15\u8d77\u4e86\u5bf9\u6700\u540e\u5242\u91cf\u7684\u6db2\u5589\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u548c\u8840\u6db2\u3001\u8840\u6db2\u548c\u8840\u6db2\u548c\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u548c\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2\u3001\u8840\u6db2", "\u624b\u672f\u671f\u95f4\u51fa\u8840\u7387\u4e0e\u5176\u4ed6\u4f5c\u8005\u7684\u62a5\u544a\u4e00\u81f4,\u4f46\u5bf9\u4e0d\u540c\u652f\u6301\u51dd\u56fa\u6218\u7565\u76f8\u5173\u51fa\u8840\u60c5\u51b5\u7684\u5206\u6790\u8868\u660e\u5b58\u5728\u4e00\u4e9b\u5dee\u5f02\u3002 Goobie\u7b49\u4eba\u5728\u5bf9\u6b63\u5728\u63a5\u53d7\u6162\u6027\u547c\u5438\u7cfb\u7edf\u75be\u75c5\u77eb\u6b63\u7684\u75c5\u4eba\u8fdb\u884c\u7684\u4e00\u9879\u5b9e\u9a8c\u4e2d,\u5728\u4f7f\u7528\u4e09\u6c27\u4e59\u9178\u5b9e\u9a8c\u4e2d,\u4e09\u6c27\u4e59\u9178\u7ec4\u7684\u51fa\u8840\u7387\u8f83\u4f4e,\u4e3a62cc/kg,DE=22,\u6bd4\u5b89\u6170\u5242101cc/kg,SD=63\u3002", "\u5c3d\u7ba1\u4f4e\u6e29\u3001\u9178\u6027\u4e2d\u6bd2\u548c\u51dd\u56fa\u7cfb\u6570\u7a00\u91ca\u4e8c\u5ea6\u81f3\u7ed3\u6676\u4f53\u91cd\u65b0\u6d3b\u5316\u5177\u6709\u91cd\u8981\u4f5c\u7528;\u73b0\u6709\u8bc1\u636e\u8868\u660e,\u7ec4\u7ec7\u635f\u5bb3\u3001\u4f4e\u805a\u53d8\u3001\u52a0\u901f\u7ea4\u7ef4\u5316\u548c\u708e\u75c7\u5bf9\u4e8e\u5f62\u6210\u51dd\u56fa\u75c5\u6001\u4e5f\u81f3\u5173\u91cd\u8981\u3002 1. \u6eb6\u6db2\u5171\u751f\u75c5:\u5728\u5927\u91cf\u6ce8\u5165\u51dd\u805a\u7684\u79d1\u7c7b\u3001\u6700\u521d\u4e3a\u4fdd\u6301\u5faa\u73af\u4f53\u79ef\u800c\u91cd\u65b0\u51dd\u805a\u7684\u6676\u4f53\u4e4b\u540e,\u51dd\u56fa\u7cfb\u6570\u548c\u5c0f\u677f\u7684\u7a00\u91ca,\u4ee5\u53ca\u6700\u521d\u4e3a\u4fdd\u6301\u5faa\u73af\u4f53\u79ef\u800c\u91cd\u65b0\u51dd\u805a\u7684\u6676\u4f53\u4f53\u3002", "\u867d\u7136\u4e34\u65f6\u63a7\u5236\u6027\u51cf\u538b\u53ef\u80fd\u5141\u8bb8\u5916\u79d1\u63a7\u5236\u51fa\u8840,\u4f46\u53ef\u80fd\u5bfc\u81f4\u66f4\u7cdf\u7cd5\u7684\u7ed3\u679c\u3002", "\u8981\u975e\u5e38\u5c0f\u5fc3\u75c5\u4eba\u7684\u4ee3\u8c22\u8981\u6c42,\u56e0\u4e3a\u8fd9\u4e9b\u8981\u6c42\u5c06\u51cf\u5c1150%,\u5e76\u76d1\u6d4b\u51dd\u56fa\u60c5\u51b5,\u5c3d\u7ba1\u4e0d\u540c\u7684\u8bd5\u9a8c\u5e76\u4e0d\u8868\u660e\u6709\u4e25\u91cd\u7684\u51fa\u8840\u98ce\u9669\u3002 \u50ac\u7720\u5ef6\u957f\u4e86\u6240\u6709\u836f\u7269\u7684\u534a\u8870\u671f\u3002", "\u4f7f\u7528\u524d\u7ea7\u5fc3\u80ba\u622a\u80a2,\u6ce8\u5165\u4e861 000\u6beb\u5347\u7684custodiol,\u8ba1\u7b97\u51fa\u7684\u51fa\u51fa\u8840\u4e3a500\u6beb\u5347,2\u4e2a\u88c5\u6ee1\u7684\u7ea2\u8840\u7ec6\u80dePRBC\u548c2\u4e2a\u65b0\u51b7\u51bb\u8840\u6d46FFFP\u5728\u5916\u79d1\u624b\u672f\u671f\u95f4\u88ab\u5207\u9664\u3002", "\u5173\u4e8e\u4e0e\u9898\u4e3a\u201c\u5916\u79d1\u624b\u672f\u4e2d\u7684\u8840\u6d46\u63d0\u53d6\u6280\u672f\u201d\u7684\u6587\u7ae0\u6709\u5173\u7684\u201c\u8840\u6db2\u50a8\u5b58\u548c\u8f93\u89e3\u4f24\u5bb3\u201d\u53cd\u601d\u6761\u6b3e\u5efa\u8bae\u94f6\u884c\u8840\u6db2\u7ecf\u8fc7\u201c\u50a8\u5b58\u201d\u7684\u6539\u53d8,\u5728\u201c\u8001\u201d\u5355\u4f4d\u88ab\u8f6c\u8fd0\u65f6\u5bfc\u81f4\u66f4\u574f\u7684\u7ed3\u679c,\u503c\u5f97\u5f3a\u8c03\u7684\u662f,\u5177\u6709\u80ba\u529f\u80fd\u969c\u788d\u7b49\u4e2d\u95f4\u7ed3\u679c\u7684\u7814\u7a76\u6ca1\u6709\u53d1\u73b0\u4e0d\u540c\u50a8\u5b58\u65f6\u95f4,\u7279\u522b\u662f\u4f0a\u65af\u5170\u6cd5\u9662\u8054\u76df\u5728\u4f7f\u7528\u8840\u6db2\u8f93\u8840\u65b9\u9762\u5b58\u5728\u7684\u7edf\u8ba1\u5dee\u5f02;\u800c\u5176\u4ed6\u7814\u7a76\u5219\u62a5\u544a\u6709\u53d8\u5316,\u7279\u522b\u662f\u5728\u5927\u89c4\u6a21\u8f93\u8840\u548c\u521b\u4f24\u75c5\u4f8b\u65b9\u9762\u3002", "\u73b0\u5728\u8ba4\u4e3a,\u5bf9\u6709\u98ce\u9669\u7684\u75c5\u4eba\u6765\u8bf4,\u6297\u5851\u5242\u7597\u6cd5\u5bf9\u4e8e\u7ef4\u6301\u8111\u8840\u7ba1\u4e2d\u98ce\u3001\u8840\u538b\u5f62\u6210\u4ee5\u53ca\u51a0\u72b6\u52a8\u8109\u52a8\u8109\u5047\u80a2\u7b49\u75be\u75c5\u81f3\u5173\u91cd\u8981\u3002", "\u2022 \u786e\u5b9a\u9ad8\u53ef\u8150\u6027,\u7279\u522b\u662f\u5728\u521b\u4f24\u548c\u5916\u79d1\u624b\u672f\u4e2d,\u5e76\u5e2e\u52a9\u9884\u6d4b7.8\u8d77\u624b\u672f\u540e\u8840\u6813\u75c7\u4e8b\u4ef6\u3002", "\u6709\u5173\u5bf9\u4e2d\u98ce\u7f3a\u8840\u75c5\u4eba\u4f7f\u7528\u8d85\u6c27\u6469\u5c14\u7597\u6cd5\u7684\u7814\u7a76\u5f88\u5c11,\u5bf9\u4f7f\u7528\u8fd9\u79cd\u7597\u6cd5\u6ca1\u6709\u7edf\u4e00\u7684\u65b9\u6cd5\u3002", "FXa\u3001Fibrin\u548cThmombin\u7684\u8fde\u7eed\u91ca\u653e\u5bfc\u81f4Fibrinolytic\u7cfb\u7edf\u6fc0\u6d3b\u3002", "\u6b64\u5916,\u4ed6\u4eec\u5efa\u8bae\u4f7f\u7528TEG\u6765\u626d\u8f6c\u809d\u7d20,\u56e0\u4e3a\u77ed\u671f\u5185\u5c31\u80fd\u53d6\u5f97\u7ed3\u679c,\u5e2e\u52a9\u6307\u5bfc\u6700\u7ec8\u6cbb\u7597,\u51cf\u5c11\u4e0d\u5fc5\u8981\u7684\u8f93\u8840\u3002", "\u5982\u679c\u9ebb\u9189\u524d\u8bc4\u4ef7\u663e\u793a\u6709\u51fa\u8840\u53f2,\u5e94\u5728\u624b\u672f\u524d\u5c06\u75c5\u4eba\u8f6c\u8bca\u5230\u8840\u538b\u5b66\u5bb6\u5904\u8fdb\u884c\u5206\u6790,\u5e76\u5728\u624b\u672f\u8fc7\u7a0b\u4e2d\u6839\u636e\u8bca\u65ad\u7684\u51dd\u56fa\u969c\u788d\u8fdb\u884c\u51c6\u5907\u3002", "\u6b64\u5916,\u53ef\u80fd\u9700\u8981\u7ea2\u7ec6\u80de\u8f93\u8840,\u4ee5\u6062\u590d\u8840\u7ea2\u86cb\u767d7\u6beb\u514b/dL\u621634\u4ee5\u4e0b\u8840\u6db2\u7684\u6c27\u6c14\u8f93\u9001\u80fd\u529b\u3002", "\u4efb\u4f55\u5f71\u54cd\u809d\u810f\u529f\u80fd\u7684\u75be\u75c5\u90fd\u53ef\u80fd\u5bf9\u51dd\u56fa\u4ea7\u751f\u5f71\u54cd,\u5728\u9ad8\u7aef\u6162\u6027\u809d\u810f\u75be\u75c5\u53d8\u5316\u4e2d,\u4e59\u578b\u7532\u72b6\u817a\u708e\u548c\u6297\u51dd\u805a\u7269\u7269\u8d28\u66f4\u660e\u663e\u3002", "\u5982\u679c\u901a\u8fc7phlebotomy\u63d0\u53d6\u7684\u8840\u6db2\u4e0d\u4f1a\u5931\u53bb\u4e0e\u75c5\u4eba\u5faa\u73af\u7684\u63a5\u89e6,\u5219\u63a5\u53d7\u6b63\u5e38\u4f53\u79ef\u7684\u4e59\u578b\u516d\u6c2f\u73af\u5df1\u70f7\u3002 \u4e59\u578b\u516d\u6c2f\u73af\u5df1\u70f7\u548c\u8131\u8840\u6291\u5236\u5242\u4e5f\u662f\u53ef\u4ee5\u63a5\u53d7\u7684\u6cbb\u7597\u9009\u62e9\u3002", "\u8fd9\u4e9b\u75c5\u4eba\u7684\u51dd\u56fa\u75c5\u7406\u7684\u7a0b\u5ea6\u548c\u4e25\u91cd\u6027\u5df2\u7ecf\u9884\u6d4b,\u4f46\u5e76\u672a\u6e05\u695a\u5730\u4e86\u89e3\u7b49\u79bb\u5b50\u4f53\u7535\u89e3\u6db2\u7684\u7a81\u7136\u53d8\u5316\u548c\u4ee3\u8c22\u9178\u6027\u4e2d\u6bd2\u539f\u56e0\u7684\u673a\u5236\u3002", "\u5982\u679c\u6ca1\u6709\u7cfb\u6570\u516b,\u4e0b\u4e2a\u9009\u62e9\u662f\u8840\u53cb\u75c5A\u7684\u8840\u6db2\u5236\u54c1,A\u7684\u8840\u53cb\u75c5\u6bcf\u888b\u63d0\u4f9b80\u4e2a\u5355\u4f4d\u7684\u7cfb\u6570\u516b\u3002", "\u7532\u9187:\u5728\u505a\u51fa\u8f6c\u53e3\u51b3\u5b9a\u4e4b\u524d,\u6700\u4f4e\u5141\u8bb8\u8840\u6e05\u542b\u91cf;\u8fd9\u662f\u4e00\u4e2a\u7406\u8bba\u6982\u5ff5,\u6e90\u4e8e\u5c06\u75c5\u4eba\u5b9e\u9645\u8840\u6e05\u51cf\u5c1130%,\u6216\u7a33\u5b9a\u5fc3\u80ba\u75c5\u7406\u5b66\u51cf\u5c1120%,\u751a\u81f3\u5c06\u5173\u952e\u75c5\u4eba\u51cf\u5c1110%;\u6700\u7ec8\u503c\u5e94\u4f4e\u4e8e25%\u3002", "\u5728\u6297cogulant\u888b\u4e2d\u91c7\u96c6\u7684\u8840\u8ff9\u4e3a:\u8102\u80aa\u9178\u76d0\u78f7\u9178\u916fdextrose adenine:CPDA\u5728\u624b\u672f\u5ba4\u7684\u51b0\u7bb1\u4e2d\u88ab\u79f0\u91cd\u3001\u8d34\u6807\u7b7e\u5e76\u50a8\u5b58\u5728\u51b0\u7bb1\u4e2d,\u8840\u6db2\u5728\u624b\u672f\u5b8c\u6210\u540e\u88ab\u6ce8\u5165\u75c5\u4eba\u4f53\u5185,\u53ef\u4ee5\u4f7f\u7528\u523024\u5c0f\u65f6\u540e,\u4f46\u6700\u597d\u5728\u59346\u5c0f\u65f6\u5185\u4f7f\u7528,\u56e0\u4e3a\u5c0f\u677f\u529f\u80fd\u5f97\u5230\u4fdd\u5b58\u3002", "\u6cbb\u7597:\u5f53\u5c0f\u677f\u8ba1\u6570\u4f4e\u4e8e20,000\u6beb\u7c73\u6216\u6709\u6269\u6563\u51fa\u8840\u6570\u636e\u65f6,\u5fc5\u987b\u8fdb\u884c\u6cbb\u7597\u3002"], "train": [0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], "chrf": [null, 0.448, null, 0.89, 0.812, null, null, null, 0.501, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null], "familiarity": [0.291, null, 0.464, null, null, 0.176, 0.136, 0.496, null, 0.862, 0.324, 0.472, 0.375, 0.953, 0.367, 0.559, 0.436, 0.586, 0.727, 0.571, 0.625, 0.571, 0.567, 0.439, 0.439, 0.996, 0.76, 0.4, 0.907, 0.262, 0.664, 0.439, 0.136, 0.439, 0.655, 0.393, 0.597, 0.945, 0.783], "x": [18.156, 18.179, 15.777, 17.019, 18.042, 17.566, 20.029, 9.455, 16.743, 12.134, 8.511, 18.308, 8.176, 11.977, 18.532, 10.884, 9.738, 10.683, 18.32, 18.343, 16.771, 18.374, 17.024, 18.474, 18.601, 11.608, 12.341, 8.318, 11.786, 18.657, 10.418, 18.539, 19.977, 18.506, 12.655, 17.22, 12.206, 16.958, 10.857], "y": [10.244, 11.67, 10.96, 12.235, 11.611, 5.68, 5.798, 15.914, 12.618, 13.783, 17.218, 11.077, 16.495, 14.569, 11.278, 12.469, 16.876, 16.297, 11.902, 11.462, 11.052, 11.49, 10.71, 11.397, 11.385, 15.381, 12.854, 14.159, 14.454, 10.277, 15.575, 11.306, 5.765, 11.329, 12.339, 10.254, 11.62, 11.879, 14.712], "source_id": ["0", null, "0", null, null, "0", "0", "0", null, "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0", "0"], "date": [20210826.0, null, 20220224.0, null, null, 20211114.0, 20211206.0, 20220216.0, null, 20210929.0, 20220221.0, 20211109.0, 20220319.0, 20211201.0, 20210619.0, 20210816.0, 20211110.0, 20220109.0, 20220202.0, 20220223.0, 20210905.0, 20211226.0, 20210802.0, 20220127.0, 20211008.0, 20210920.0, 20211002.0, 20210805.0, 20220310.0, 20220302.0, 20210811.0, 20211210.0, 20210820.0, 20210910.0, 20211224.0, 20211014.0, 20210609.0, 20220213.0, 20211016.0], "keywords": [["coagulation", 0.0340810766081511], ["cc", 0.027883395032453236], ["blood", 0.02785855879157121], ["platelets", 0.025658703427807524], ["bleeding", 0.022211535999015396], ["kg", 0.021900078890339358], ["transfused", 0.018419795657476392], ["anticoagulant", 0.018419795657476392], ["coagulopathy", 0.017105802285205012], ["volume", 0.01454115763138241], ["viii", 0.014514954015771997], ["tranexamic", 0.014514954015771997], ["hematocrit", 0.014514954015771997], ["lmwh", 0.013814846743107295], ["surgery", 0.013551860687262674], ["storage", 0.013272276725991837], ["units", 0.011632926105105927], ["sd", 0.011590897528252236], ["therapy", 0.011105767999507698], ["patients", 0.010959919776471492], ["outcomes", 0.010956801553455183], ["operative", 0.010956801553455183], ["intra", 0.010778012193289704], ["alterations", 0.010778012193289704], ["citrate", 0.01033504591816882], ["haemorrhage", 0.01033504591816882], ["heparins", 0.01033504591816882]]}